The advanced melanoma market has demonstrated robust growth, expanding from $4.12 billion in 2025 to a projected $4.5 billion in 2026, registering a CAGR of 9.3%. This surge is primarily driven by a ...
StockStory.org on MSN
A look back at biotechnology stocks’ Q4 earnings: Incyte (NASDAQ:INCY) vs. the rest of the pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results